Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The meeting will be held virtually October 29-31, 2020. The oral presentation will highlight new data from an ongoing open label extension study evaluating long-term safety and treatment effects of CTP-543 in patients with moderate to severe alopecia areata.
The details of the presentation are as follows:
- Title: Initial Results from a Long-Term, Open-Label Extension Study with CTP-543, an Oral Janus Kinase Inhibitor, in Patients with Moderate to Severe Alopecia Areata
- Date and Time: Thursday, October 29, 2020, 3:00 – 3:15 pm Central European Time
- Session: D1T03.3C: Late-Breaking News Session
- Location: EADV Virtual Meeting. Registration is required to participate: https://eadvvirtualcongress.org/registration/